ReportGemReportGem 中文

PUBLIC COMPANY RESEARCH HUB

ARGX.BR (ARGX.BR) Foreign Research Coverage

A focused collection of foreign research coverage for ARGX.BR, organized by institution and publication date for faster discovery.

Evidence documents3
Filings0
Meetings0
Research3
Displayed research share100%
Latest evidence2026-08-05

Foreign research

Argenx Updating for Q2’26: Continue to see strong Vyvgart growth with focus on H2’26 pipeline readouts2026-08-05 · JPMorgan

J P M O R G A N Europe Equity Research 06 August 2026 Argenx Updating for Q2’26: Continue to see strong Vyvgart growth with focus on H2’26 pipeline readouts We update our model to reflect the Myositis R&D Spotlight session (our take …

argenx SE: argenx Doubles Down on Immunology: Forte Deal Adds FB102 Optionality While VYVGART Momentum Funds the Next Growth Wave2026-07-27 · Morgan StanleyARGX: 2Q26 First Take: Vyvgart Strong Beat And Myositis On Track For 3Q262026-07-23 · RBC Capital Markets

Questions this evidence can help answer

  • What changed in the latest research coverage of ARGX.BR?
  • Which operating and valuation themes recur across institutions?
  • Which claims should be checked against company primary-source evidence?
Research this company with AI